Switzerland-based MetP Pharma, pioneer in nose-to-brain drug delivery for nearly two decades, announced new data highlighting the advantages of its proprietary MetP Technology in delivering neuroactive peptides such as semaglutide directly to the brain via the intranasal route.
In a pharmaceutical landscape facing declining prices, expiring patents, and disrupted supply chains, reformulating existing drugs for intranasal delivery presents a timely innovation opportunity. With semaglutide as a reference compound, MetP demonstrates that its platform can significantly enhance brain uptake while minimizing systemic exposure – addressing both efficacy and safety.
“Delivering peptides to the brain is notoriously difficult due to their molecular properties and formulation challenges,” said Dr Claudia Mattern, Chief Scientific Officer of MetP Pharma, adding: “The MetP Technology overcomes these barriers by leveraging perineural and perivascular transport pathways, bypassing the blood-brain barrier and enabling direct, efficient brain delivery.”
